Simplyhealth has announced it will invest £60 million into the UK healthcare market in a bid to develop solutions and access to healthcare.
The fund forms part of Simplyhealth's venture capital schemes with a focus on investment in early-stage healthcare businesses to support its growth and development, specifically on innovation in predictive and preventative healthcare The mutual has invested an undisclosed amount into Daye, a gynaecological health company which creates products such as relief for period pain, at-home STI testing and the treatment of vaginal infections. The funding will enable Daye to expand its offering from menstruation to vaginal microbiome screening. Dr Sneh Khemka, chief executive at Simplyheal...
To continue reading this article...
Join COVER for free
- Unlimited access to real-time news, key trend analysis and industry insights.
- Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
- Receive breaking news stories straight to your inbox in the daily newsletter.
- Members only access to monthly programme 'The COVER Review'
- Be the first to hear about our CPD accredited events and awards programmes.